Add time:08/23/2019         Source:sciencedirect.com

1.1. The effect of a new antiulcer agent, Ebrotidine (cas 100981-43-9), on the synthesis and secretion of sulfomucin in gastric mucosa was investigated. Rat gastric mucosal segments were incubated in DMEM containing [3H]proline, [3H]glucosamine and [35S]Na2SO4 as markers for mucin synthesis, glycosylation and sulfation, in the presence of 0–150 μM ebrotidine.2.2. The drug, while showing no discernible effect on the apomucin synthesis, evoked a dose-dependent increase in mucin glycosylation and sulfation, which at 100 μM ebrotidine, attained its maximum of 2.4 and 2.7-fold stimulation, respectively.3.3. The analysis of mucin secretory responses revealed that ebrotidine caused a concentration-dependent enhancement in sulfomucin secretion which attained its maximum increase of 3.3-fold at 100–120 μM ebrotidine. Furthermore, the sulfomucin elaborated in the presence of ebrotidine exhibited a higher content of a large molecular-weight mucus glycoprotein form, the assembly of which is intimately associated with the sulfation event.4.4. The results suggest that the ability of ebrotidine to enhance gastric sulfomucin synthesis and secretion may play an important role in the gastroprotective mechanism of action of this agent.

We also recommend Trading Suppliers and Manufacturers of Ebrotidine (cas 100981-43-9). Pls Click Website Link as below: cas 100981-43-9 suppliers